Tango Therapeutics (TNGX) Fundamental Analysis: Revenue, Earnings & Valuation

4.43 / 10

Netural

Fundamental analysis rates TNGX as neutral with a 4.4/10 score. Revenue‑to‑market and profit‑to‑market ratios are strong, cash position modest, and inventory turnover robust. However, current‑asset and fixed‑asset turnover are weak, limiting overall financial strength.

Analysis Checks(8/10)

Revenue-MV

Value-0.08

Score2/3

Weight16.89%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight14.61%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.10%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight13.74%

1M Return6.36%

Income tax / Total profit (%)

Value-0.00

Score2/3

Weight1.73%

1M Return0.98%

Current assets turnover ratio

Value0.20

Score0/3

Weight-2.56%

1M Return-1.61%

Fixed assets turnover ratio

Value1.39

Score1/3

Weight-1.79%

1M Return-1.13%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.26%

1M Return4.08%

Asset-MV

Value-0.55

Score2/3

Weight33.57%

1M Return13.10%

Cash-MV

Value0.03

Score2/3

Weight13.46%

1M Return6.19%

Is TNGX undervalued or overvalued?

TNGX scores 4.43/10 on fundamentals and holds a Fair valuation at present. Backed by its -37.23% ROE, -162.85% net margin, -27.05 P/E ratio, 7.94 P/B ratio, and 26.89% earnings growth, these metrics solidify its Netural investment rating.